Amundi Increases Stock Position in Pfizer Inc. $PFE

Key Points

• Amundi has increased its ownership in Pfizer Inc. by 43.4%, holding over 52 million shares valued at approximately $1.27 billion as of the end of the most recent quarter.
• Several hedge funds significantly boosted their positions in Pfizer, with Brighton Jones LLC raising its stake by 1,282.4% in the fourth quarter.
• Pfizer reported a 10.3% increase in quarterly revenue year-over-year, with earnings per share of $0.78, surpassing analysts' estimates.

Amundi boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 43.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,090,403 shares of the biopharmaceutical company's stock after purchasing an additional 15,758,846 shares during the period. Amundi owned approximately 0.92% of Pfizer worth $1,265,277,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Triumph Capital Management boosted its position in shares of Pfizer by 20.0% during the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 1,717 shares during the last quarter. Cary Street Partners Financial LLC purchased a new position in shares of Pfizer in the 4th quarter worth $3,426,000. Finally, Cahill Financial Advisors Inc. increased its stake in Pfizer by 60.4% during the fourth quarter. Cahill Financial Advisors Inc. now owns 15,284 shares of the biopharmaceutical company's stock worth $405,000 after acquiring an additional 5,756 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. HSBC reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Up 0.7%

PFE opened at $24.94 on Wednesday. The company has a market cap of $141.77 billion, a PE ratio of 13.26, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a 50-day moving average price of $24.82 and a 200 day moving average price of $24.37. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.